What it is
Sermorelin is a synthetic 29-amino-acid peptide that corresponds to the biologically active portion of human growth hormone-releasing hormone (GHRH) — the shortest GHRH fragment that retains full activity.1 It works by binding the GHRH receptor on the pituitary gland, prompting it to secrete the body's own growth hormone in a pulsatile, physiologic pattern, rather than delivering growth hormone itself the way an injection of recombinant GH would.
Also known as: sermorelin acetate, or by its discontinued brand name Geref. Geref was FDA-approved decades ago for diagnostic testing of growth hormone reserve and for treating pediatric idiopathic growth hormone deficiency, but its manufacturer discontinued the product commercially in the mid-2000s — not because of a safety concern.21 Because no FDA-approved sermorelin product is currently marketed, essentially all sermorelin used today in the US — mostly for off-label adult wellness and "anti-aging" purposes — is prepared by 503A compounding pharmacies from bulk peptide under a physician's prescription.
It's worth being direct about the gap here: sermorelin's original approval and its current, much more common off-label use serve two very different populations — children with a confirmed hormone deficiency, versus adults seeking general wellness or age-related benefits — and the evidence supporting each is not equivalent.
How it works
Sermorelin binds the GHRH receptor, a receptor on pituitary somatotroph cells that, once activated, raises intracellular cAMP and ultimately triggers the synthesis and pulsatile release of the body's own growth hormone. Because sermorelin acts upstream of the pituitary rather than being growth hormone itself, the body's natural negative-feedback loops — through somatostatin and IGF-1 — stay intact. That's the mechanistic rationale for why sermorelin is thought to produce a more physiologic GH pulse pattern and, in theory, a lower overdose risk than injecting GH directly, though this specific comparative claim hasn't been rigorously tested in long-term human trials.1
Both natural GHRH and sermorelin are rapidly broken down by an enzyme called dipeptidyl peptidase-IV, giving sermorelin a very short plasma half-life — roughly 11 to 12 minutes after injection.1 That short half-life is exactly why sermorelin needs to be dosed daily, usually at night to line up with the body's natural peak in overnight GH release — unlike longer-acting GHRH analogs such as tesamorelin or CJC-1295, which are chemically modified to last much longer.
It's given by subcutaneous injection, typically once daily at bedtime. Historically, intravenous administration was also used, but only for diagnostic GH-stimulation testing rather than ongoing treatment.
What the research shows
Evidence snapshot: Sermorelin's human evidence is real but modest in scale, decades old, and concentrated almost entirely in children with a confirmed growth hormone deficiency — not in the adult wellness population where it's now most commonly prescribed off-label. There are no large, modern, placebo-controlled trials in adults for muscle mass, fat loss, sleep, or anti-aging claims. The rationale for adult use is extrapolated from GH physiology and old pediatric data, not from dedicated adult efficacy trials.
Animal / preclinical evidence
The available research brief for sermorelin does not identify a distinct modern animal-model efficacy literature separate from its human trial history — its mechanism (GHRH receptor agonism) is well established through basic endocrine physiology, but the compound's specific efficacy claims rest on the human studies described below, nearly all of which are decades old.
Human evidence
The core clinical evidence is a comprehensive 1999 review of sermorelin's use in children with idiopathic growth hormone deficiency.1 It found that once-daily bedtime sermorelin injections (30 mcg/kg) produced sustained increases in height velocity over 12 months, with catch-up growth maintained in some children through 3 years. That same review established that intravenous sermorelin is a reasonably specific diagnostic test for growth hormone reserve, with fewer false positives than some other stimulation tests — though a normal response still can't fully rule out a hypothalamic cause of growth hormone deficiency.
Beyond that pivotal review, the supporting literature consists of small studies from the 1980s and 1990s — typically enrolling only dozens of children — that helped establish sermorelin's original diagnostic and short-term treatment efficacy and laid the groundwork for its original FDA approval as Geref. No large, modern (2015 or later), randomized, placebo-controlled trial of sermorelin exists in adults for muscle mass, fat loss, sleep quality, or general anti-aging outcomes — the exact indications for which it's most commonly compounded and prescribed today.
Honest bottom line: sermorelin's core human evidence dates to the 1990s and applies to short-stature children with a confirmed growth hormone deficiency diagnosis — a fundamentally different population and use case than today's off-label adult wellness market. Its FDA-approved product was withdrawn for commercial, not safety, reasons, but that also means there's been no modern, industry-sponsored trial program to update or expand what we know. Prescribing sermorelin for adult anti-aging purposes extrapolates from pediatric data and GH-axis physiology, not from adult efficacy trials — and that gap should be stated plainly rather than glossed over.
Typical use and dosing
In the pediatric growth hormone deficiency literature that formed the original approval basis, dosing was 30 mcg/kg subcutaneously once daily at bedtime.1 Diagnostic GH-stimulation testing historically used a single 1 mcg/kg intravenous bolus, with growth hormone measured afterward. Off-label adult dosing, as described in compounding-pharmacy and clinical-practice literature rather than controlled trials, typically runs 200–500 mcg subcutaneously nightly, often cycled (for example, 5 days on and 2 days off) over courses of 3 to 6 months.
| Use case | Typical published dosing |
|---|---|
| Pediatric GHD (historical Geref data) | 30 mcg/kg subcutaneously, nightly |
| Diagnostic GH-stimulation test | 1 mcg/kg intravenous bolus |
| Off-label adult use (practice pattern, not trial-derived) | 200–500 mcg subcutaneously nightly, often cycled |
It's important to be clear that the adult dosing figures above come from compounding-pharmacy protocols and clinical practice patterns, not from published randomized trials — there is no FDA-approved or trial-validated adult dosing regimen for sermorelin.
Safety, side effects, and who should avoid it
Who should avoid it: sermorelin is contraindicated in people with active malignancy, a pituitary tumor, known hypersensitivity to the peptide, or during pregnancy (not studied). Because it stimulates the GH/IGF-1 axis, it carries the same theoretical class-wide concerns as any GH secretagogue regarding a hypothetical growth-promoting effect on occult tumor cells — a concern that has not been demonstrated in sermorelin-specific human trials but has also not been ruled out.
The most commonly reported side effects are injection-site pain, redness, or swelling, along with flushing, headache, dizziness, and drowsiness.2 Less common effects include itching and restlessness ("trouble sitting still"). Beyond these direct effects, chronic stimulation of the GH/IGF-1 axis raises the same theoretical, class-wide concerns as any growth hormone secretagogue: worsened insulin sensitivity or glucose tolerance, fluid retention, and joint pain — though these haven't been specifically confirmed or quantified in sermorelin trials.
IGF-1 levels are commonly used in practice to titrate dosing and screen for excessive growth hormone exposure, though this monitoring approach is drawn from general growth-hormone-therapy conventions rather than sermorelin-specific outcome data.3 Long-term human safety data in adults using sermorelin off-label are limited; the pediatric trials that exist followed children for up to three years, but that population, dosing, and clinical context differ substantially from adult wellness use.
Regulatory status
No FDA-approved sermorelin product is currently marketed in the US. Geref's original approval remains on record historically, but there is no active manufacturer marketing it today, and its discontinuation was a commercial decision rather than a safety withdrawal.2 Sermorelin does not currently appear on the FDA's 503A interim bulk drug substance Category 1, 2, or 3 lists as of mid-2026 — meaning it hasn't been formally flagged with a significant-safety-risk designation the way some other peptides were in a 2023 FDA action — but its compounding legality still depends on complex "difficult to compound" and prior-approval-history criteria that prescribers and pharmacies should confirm directly against current FDA guidance rather than assume.4
Sermorelin and related GHRH analogs, including CJC-1295 and tesamorelin, are listed on the World Anti-Doping Agency's Prohibited List under section S2.2.4 ("growth hormone-releasing hormone and its analogues"), prohibited at all times, both in and out of competition.5 No sermorelin-specific FDA safety communication has been issued during the broader 2023–2026 peptide-regulation wave, which targeted several other peptides but not sermorelin directly.
Frequently asked questions
Is sermorelin the same thing as HGH?
No. Sermorelin is a GHRH analog that signals the pituitary to release the body's own growth hormone; it doesn't contain growth hormone itself.
Is sermorelin FDA-approved?
An FDA-approved sermorelin product (Geref) existed historically for pediatric growth hormone deficiency but has been discontinued commercially. No sermorelin product is FDA-approved and currently marketed today — all current use is through compounding pharmacies for off-label indications.2
Why was Geref discontinued?
Reported commercial reasons — a small pediatric market and cost considerations — rather than a documented safety issue.2
Does sermorelin build muscle or reverse aging?
There's no substantial modern randomized controlled trial evidence in adults for muscle-building or anti-aging claims; the human evidence base is pediatric growth hormone deficiency data from the 1990s.
How is sermorelin different from ipamorelin or CJC-1295?
Sermorelin is a native GHRH(1-29) analog with a very short half-life (about 11–12 minutes) that requires nightly dosing. CJC-1295 has a chemical modification that extends its half-life to days. Ipamorelin works through an entirely different receptor (the ghrelin receptor) rather than the GHRH receptor.
Can sermorelin cause a positive doping test?
Yes — GHRH analogs including sermorelin are prohibited at all times under the World Anti-Doping Agency's Prohibited List, section S2.2.4.5
Is sermorelin safe long-term?
Long-term human safety data in adults using it off-label are limited. Pediatric trials followed patients for up to three years, but that population and dosing differ substantially from how it's used in adult wellness settings today.
References
Last medically reviewed: July 27, 2026
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. narrative review
- Mayo Clinic. Sermorelin (injection route) — Side effects & dosage. narrative review
- Yuen KCJ, Biller BMK, Radovick S, et al. AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults. Endocr Pract. 2019;25(11):1191-1232. narrative review
- FDA. Substances in Compounding that May Present Significant Safety Risks (503A/503B interim bulk drug substances list). FDA document
- World Anti-Doping Agency. 2026 Prohibited List. WADA source
Medical disclaimer. This page is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment, and does not create a doctor-patient relationship. Always consult a licensed healthcare provider before starting, stopping, or changing any treatment. Individual results vary.
About compounded medications. Sermorelin may be provided as a compounded preparation. Compounded medications do not undergo FDA premarket review or approval, and may differ from FDA-approved drug products in safety, effectiveness, and side-effect profile. Data from clinical trials of FDA-approved medications should not be assumed to apply directly to compounded formulations. Sermorelin is dispensed only pursuant to a valid prescription following clinical evaluation by a licensed physician.
Next step
See if sermorelin fits your protocol
Sermorelin is one of several therapies Aurafil physicians consider during a full metabolic and hormonal evaluation. Whether it's the right fit depends on your labs, symptoms, goals, and medical history.